How far will Novartis’ Sandoz go to ‘differentiate’ itself? Into branded drugs, apparently

11th April 2019 Uncategorised 0

Sandoz is known as a leader in off-patent medicines. But amid a strategic pivot that aims to give the Novartis division more autonomy, it has signed a different sort of deal: It’s licensing an innovative medicine only recently approved.

More: How far will Novartis’ Sandoz go to ‘differentiate’ itself? Into branded drugs, apparently
Source: fierce